← Eichor
Study identifier: NCT03087032 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Condition: Type 2 Diabetes Patients · Overweight and Obesity · Hyperglycaemia (Diabetic)  ·  Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 4
Planned participants164
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.

This description comes directly from the study's public registry record.

Talk to the study team

Changqin Liu, MD  ·  +86-133-7698-6106  ·  liuchangqin@xmu.edu.cn

Xin Zheng, MD  ·  +86-187-0592-9102  ·  88126386@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

The first afilliated hospital of Xiamen universityXiamen, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03087032